ClinicalTrials.gg
CompletedNCT04384016Updated Jul 6, 2023

Safety and Immunogenicity of Skyvaricella Injection in Healthy Volunteer Vietnamese Children From 12 Months to 12 Years Old

A Phase 4 interventional study of Skyvaricella Injection in Chickenpox, sponsored by Vietnam Military Medical University. Completed at 1 site in Vietnam. Open to participants aged 12 Months to 12 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-07-06.

Sponsored by Vietnam Military Medical University · Phase 4, Interventional, and Prevention

Phase
Phase 4
Study type
Interventional
Enrollment
201
Allocation
Randomized
Ages
12 Months to 12 Years
Sex
All
01

Study summary

This is a cross-over, open-label, single-group study. The study subjects were children 12 months to 12 years of age who will be vaccinated with a single dose. The duration of follow-up for safety evaluation and immunogenicity (on a small group) is 6 weeks (+ 2 weeks).

The main target:

  • Evaluating the safety of live attenuated Varicella vaccine [Oka / SK], lyophilized powder and solvent for subcutaneous injection (SKYVaricella inj.) in healthy Vietnamese children from 12 months to 12 years, with a single injection.

Secondary target:

  • Assess the immunogenicity of live attenuated Varicella vaccine [Oka / SK], lyophilized powder and solvent for subcutaneous injection (SKYVaricella inj.) in a small group of healthy Vietnamese children from 12 months to 12 years, with a single injection.
Read the detailed description

The Safety of Skyvaricella Injection:

  • The incidence of a chickenpox-like local rash (injection site) or chickenpox-like rash (disseminated) between 1 and 6 weeks after vaccination
  • The incidence and severity of events (local and systemic) within 30 minutes after vaccination
  • The incidence of expected systemic and local adverse events within 7 days after vaccination
  • The incidence of serious adverse events and Unexpected adverse events within 6 weeks after vaccination The Immunogenicity of Skyvaricella Injection: seroconversion rate by Fluorescent antibody to membrane antigens (FAMA) test 6 weeks after investigational vaccination
02

Conditions studied

  • Chickenpox

Browse trials for

Keywords

  • Chickenpox; varicella-zoster virus; varicella vaccine
03

In context

Chickenpox

180 studies on the registry are indexed under Chickenpox; 28 are open to participants now.

This study's enrollment of 201 is below the median of 475 across 149 interventional studies indexed under Chickenpox.

Browse Chickenpox studies →

Lead sponsor

Vietnam Military Medical University is the lead sponsor of 8 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
12 Months to 12 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Children from full 12 months to full 12 years of age, healthy, agreed to participate by parents/guardians and allowed to monitor during the study period.
  • The legal parent/guardian signs the study consent form, fully understanding the details of the study. Be fully explained and voluntarily agree to participate in the study and be able to follow the instructions provided by the study.
  • The parent / legal guardian agrees in writing and is deemed to be able to cooperate with the study and meet all the requirements described in the protocol during the study.
  • If girls are menstruating, a negative pregnancy test should be performed on the day of vaccination and consent to practices within 3 months after vaccination.

Exclusion criteria

Exclusion Criteria:

  • reaction to any component of the research vaccine, such as gelatin or neomycin.
  • Has been vaccinated against chickenpox before.
  • History of chickenpox.
  • People who have been exposed to chickenpox at home, day care, school, etc. within 4 weeks before getting the IP vaccine.
  • Persons with acute or chronic cardiovascular disorders (CS) of clinical significance (respiratory, endocrine and neurological (including hematological diseases, leukemia), all types of lymphoma and other affecting the bone marrow or lymphatic system).
  • People with a history of hypersensitivity to immunization, or Guillain-Barre syndrome.
  • Patients who have used or are expected to use or immunomodulatory therapies 6 months prior to the study vaccine up to 3 visits (6 + 2 weeks after vaccination) -xin) (e.g. chemotherapy drugs such as Cyclophosphamide, 6-Mercaptopurine, Azathioprine, Methotrexate, Cyclosporine A, Rapamycin and Leflunomide / biological treatments such as tumor necrosis factor [TNF-α], antiallergic drugs (antibodies, monoclonal antibodies and antisera / lymphocytes).
  • Congenital or acquired immunodeficiency, lowering blood gammaglobulin and blood gammaglobulin disorder.
  • Persons with a family history of congenital or hereditary immunodeficiency.
  • Persons who live in the same household as a member of a high-risk group for varicella infection (for example, infants aged 0 to 4 weeks, pregnant women without a history of chickenpox vaccination and disease nuclear immunodeficiency factor).
  • People currently suffering from tuberculosis.
  • Ear canal temperature of 38.0 ° C or higher on the day of the vaccination.
  • Those who received or expected to receive salicylate from 14 days before the IP vaccine to the 3rd visit (6 + 2 weeks after the IP vaccine).
  • Persons who have received or are expected to receive human immunoglobulins, whole blood or blood-derived products such as packed red blood cells (RBC), intravenous immunoglobulins (IVIG) or globulins immunity to varicella zoster (VZIG) from 5 months prior to the IP vaccine to the 3rd visit (6 + 2 weeks after the IP vaccine).
  • Persons who have received or are expected to receive other vaccines 4 weeks prior to the IP vaccine visit 3 (6 + 2 weeks after the IP vaccine).
  • Those who received or expected to receive from 3 months prior to the IP vaccine to the 3rd visit (6 + 2 weeks after the IP vaccine) (However, in the case of steroid use Low doses [eg \<2 mg Prednison / kg / day up to a maximum of 20 mg / day for \<2 weeks], the patient can participate in the study if use can be suspended until 3rd Visit after getting the IP vaccine).
  • Persons who received or expected to receive antiretroviral drugs from 1 month prior to the IP vaccine to 3rd visits (6 weeks after vaccination + 2 weeks) during the clinical study period ( However, in the case of topical antiviral drugs, patients can participate in the study).
  • People who received or expected to receive other IPs in another clinical study from 1 month before the IP vaccine to the 3rd visit (6 + 2 weeks after the IP vaccine).
  • Others are considered ineligible to participate in research according to the researcher's judgment.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
201 participants (actual)

Study arms

  • Experimental
    Evaluating the Safety of Skyvaricella Inj.

    The main target: • Evaluating the safety of Live Attenuated Varicella Vaccine SKYVaricella injection in healthy Vietnamese children from 12 months to 12 years, with a single injection

    Biological: Skyvaricella Injection

  • Experimental
    Evaluating the Immunogenicity of Skyvaricella Inj.

    Secondary target • Evaluating the immunogenicity of Live Attenuated Varicella Vaccine SKYVaricella injection in a small group of healthy Vietnamese children from 12 months to 12 years, with a single injection.

    Biological: Skyvaricella Injection

Interventions

  • BiologicalSkyvaricella Injection

    The main target is evaluating the safety of SKYVaricella injection in healthy Vietnamese children from 12 months to 12 years, with a single injection. The secondary target is to Assess the immunogenicity of SKYVaricella inj. in a small group of healthy Vietnamese children from 12 months to 12 years, with a single injection.

06

What researchers measure

Primary outcomes

  1. the Safety of Skyvaricella Injection

    The incidence of a chickenpox-like local rash (injection site) or chickenpox-like rash (disseminated).

    Time frame: between 1 and 6 weeks after vaccination

  2. the Safety of Skyvaricella Injection

    The incidence and severity of events (local and systemic)

    Time frame: within 30 minutes after vaccination

  3. the Safety of Skyvaricella Inj.

    The incidence of expected systemic and local adverse events

    Time frame: within 7 days after vaccination

  4. the Safety of Skyvaricella Injection

    The incidence of serious adverse events and Unexpected adverse events

    Time frame: within 6 weeks after vaccination

Secondary outcomes

  1. the Immunogenicity of Skyvaricella Injection

    seroconversion rate by Fluorescent antibody to membrane antigens (FAMA) test

    Time frame: 6 weeks after investigational vaccination

07

Study locations

1 site
  • CDC Ha Nam
    Phu Ly, Ha Nam 18000, Vietnam
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2021 to primary completion in Jul 2021, 2 months.

Of 14 phase 4 interventional studies under Chickenpox, half reached primary completion within 4 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 22. This study's 2 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 2, 2020
First posted
May 12, 2020
StartActual
Apr 17, 2021
Primary completionActual
Jul 6, 2021
CompletionActual
Apr 19, 2022
Last update
Jul 6, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 6, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04384016
Lead sponsor
Vietnam Military Medical University
Collaborators
Vabiotech
Responsible party
Pham Ngoc Hung (Principal Investigator, Vietnam Military Medical University) — Principal investigator
First posted
May 12, 2020
Start date
Apr 17, 2021
Primary completion
Jul 6, 2021
Completion
Apr 19, 2022
Last update
Jul 6, 2023

Study contacts

Pham N Hung, As. Prof.
principal investigator · Vietnam Military Medical University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion